Ironwood Pharmaceuticals (IRWD) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $709.48M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Drug Manufacturers - Specialty & Generic |
| Country | US | CEO | Thomas A. McCourt |
| IPO Date | 2010-02-03 | CAGR | 27.04% |
| Employees | 100 | Website | www.ironwoodpharma.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $625.19M | P/E | 5.53 | Forward P/E | 2.93 | PEG | 0.04 |
| P/S | 1.57 | P/B | -3.82 | P/CF | 3.24 | P/FCF | 3.22 |
| Sales | $389.32M | Sales 1Y | 26.19% | Sales 3Y | -8.88% | Sales 5Y | -5.74% |
| EPS | $0.78 | EPS 1Y | -1544.82% | EPS 3Y | -112.66% | EPS 5Y | -75.41% |
| Sales QoQ | 6.14% | EPS QoQ | 29.17% | Sales QoQ Avg | 27.92% | EPS QoQ Avg | -496.78% |
| Gross Margin | 99.76% | Operating Margin | 60.64% | Profit Margin | 33.36% | ROCE | 93.58% |
| ROA | 46% | ROE | -57% | Altman Z Score | -1.99 | Piotroski Score | 8 |
| Current Ratio | 6.06 | Quick Ratio | 6.06 | Cash Ratio | 2.41 | Op. CF Ratio | 1.93 |
| Debt/Equity | -0.07 | Debt/Assets | 0.04 | Lt Debt/Equity | -0.05 | Lt Debt/Cap. | -0.06 |
| Intrst Cov. | 7.23 | Inventory Turnover | — | Asset Turnover | 1.37 | Receivables Turnover | 3.45 |
| Enterprise Value | $625.19M | P/E Ratio | 5.53 |
| Forward P/E | 2.93 | PEG Ratio | 0.04 |
| P/S Ratio | 1.57 | P/B Ratio | -3.82 |
| P/CF Ratio | 3.24 | P/FCF Ratio | 3.22 |
| EPS | $0.78 | EPS Growth 1Y | -1544.82% |
| EPS Growth 3Y | -112.66% | EPS Growth 5Y | -75.41% |
| Revenue Growth 1Y | 26.19% | Gross Margin | 1% |
| Operating Margin | 0.61% | Profit Margin | 0.33% |
| ROE | -0.57% | ROA | 0.46% |
| ROCE | 0.94% | Current Ratio | 6.06 |
| Quick Ratio | 6.06 | Cash Ratio | 2.41 |
| Debt/Equity | -0.07 | Interest Coverage | 7.23 |
| Altman Z Score | -1.99 | Piotroski Score | 8 |
Ironwood Pharmaceuticals (IRWD) valuation & financials
Ironwood Pharmaceuticals (IRWD) has a market capitalization of $709.48M and trades at a price-to-earnings ratio of 5.5. It operates in the Healthcare sector (Drug Manufacturers - Specialty & Generic).
Ironwood Pharmaceuticals's revenue grew +26.2% over the last year.
Ironwood Pharmaceuticals's next earnings report is scheduled for November 9, 2026 before market open; analysts estimate EPS of $0.30. Check the earnings calendar to see all companies reporting this week.
Ironwood Pharmaceuticals (IRWD) — frequently asked questions
When does Ironwood Pharmaceuticals (IRWD) report earnings next?
Ironwood Pharmaceuticals is expected to report earnings on November 9, 2026 before market open. Analysts estimate EPS of $0.30.
What is Ironwood Pharmaceuticals's market cap?
Ironwood Pharmaceuticals (IRWD) has a market capitalization of $709.48M.
What is IRWD's P/E ratio?
Ironwood Pharmaceuticals trades at a price-to-earnings ratio of 5.5, with trailing twelve-month EPS of $0.78.
How fast is Ironwood Pharmaceuticals growing?
Ironwood Pharmaceuticals's revenue grew +26.2% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)